Date Title
26 Aug 2026
Early-Stage Situation: Fast-Growing, Broadly Appealing, Science-Backed Nutrition Supplements — Initiating Coverage at Buy, $37 PT
19 Aug 2026
PRE: 2Q Recap; Revenue Guide Moves Higher; Reit Buy, $36 PT
19 Aug 2026
Prenetics Posts Record Quarter And Raises 2026 Guidance For The Third Time; July Revenue Reaches Record $20.9 Million As CAC Declines; Raise Estimates and Maintain $30 Price Target
17 Aug 2026
IM8 Demand Remains Strong As Customer Economics Improve And Growth Outlook Expands; Reiterate Buy And $35 Price Target
15 Jul 2026
$1B Non-Dilutive Financing Removes Growth Constraint And Supports Higher IM8 Guidance; Reiterate Buy And Raising PT To $35
15 Jul 2026
Game Changing Growth Financing from General Catalyst; PT to $40
15 Jul 2026
$1 Billion Non-Dilutive Financing Removes Growth Constraint; Management Raises Guidance Again; We Increase Revenue Estimates, And Introduce 2028 EPS Estimates; Maintain Price Target
16 Jun 2026
Initiating Coverage at Buy with $30 Price Target
15 May 2026
PRE: 1Q Preliminary Results; Strong IM8 Momentum; Reit Buy